Atria Investments Inc Boosts Stake in Doximity, Inc. (NASDAQ:DOCS)

Atria Investments Inc boosted its stake in shares of Doximity, Inc. (NASDAQ:DOCS) by 6.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,975 shares of the company’s stock after buying an additional 539 shares during the period. Atria Investments Inc’s holdings in Doximity were worth $479,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in DOCS. Oppenheimer & Co. Inc. lifted its holdings in shares of Doximity by 139.2% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 35,635 shares of the company’s stock valued at $1,553,000 after purchasing an additional 20,740 shares during the last quarter. KBC Group NV increased its position in shares of Doximity by 22.9% in the 3rd quarter. KBC Group NV now owns 3,296 shares of the company’s stock valued at $144,000 after acquiring an additional 614 shares during the period. Natixis Advisors LLC increased its position in shares of Doximity by 43.5% in the 3rd quarter. Natixis Advisors LLC now owns 31,815 shares of the company’s stock valued at $1,386,000 after acquiring an additional 9,644 shares during the period. Thrivent Financial for Lutherans grew its position in Doximity by 5.0% during the 3rd quarter. Thrivent Financial for Lutherans now owns 30,991 shares of the company’s stock worth $1,350,000 after purchasing an additional 1,474 shares during the period. Finally, Prospera Private Wealth LLC acquired a new stake in Doximity during the 3rd quarter worth about $133,000. Hedge funds and other institutional investors own 87.19% of the company’s stock.

Doximity Trading Up 4.2 %

Shares of Doximity stock opened at $63.33 on Friday. The firm has a market capitalization of $11.82 billion, a PE ratio of 63.33, a P/E/G ratio of 4.10 and a beta of 1.34. Doximity, Inc. has a twelve month low of $22.96 and a twelve month high of $85.21. The firm’s 50-day moving average price is $63.63 and its 200 day moving average price is $52.60.

Insiders Place Their Bets

In other Doximity news, Director Timothy S. Cabral sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $57.62, for a total value of $1,152,400.00. Following the transaction, the director now directly owns 6,360 shares of the company’s stock, valued at $366,463.20. This trade represents a 75.87 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 37.40% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on DOCS. Raymond James reaffirmed an “outperform” rating and set a $83.00 price target (up from $65.00) on shares of Doximity in a research report on Friday, February 7th. JPMorgan Chase & Co. increased their price target on Doximity from $30.00 to $48.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Needham & Company LLC raised their target price on Doximity from $65.00 to $82.00 and gave the company a “buy” rating in a research report on Friday, February 7th. Leerink Partnrs upgraded Doximity from a “hold” rating to a “strong-buy” rating in a research report on Friday, February 7th. Finally, Bank of America raised their target price on Doximity from $54.00 to $57.00 and gave the company a “neutral” rating in a research report on Monday, January 6th. Eleven analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $64.22.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.